Macrophage Migration Inhibitory Factor (MIF) is a small cytokine - a signaling protein secreted by cells - that was originally identified for its role in immune responses. Unlike most cytokines, MIF is unusual because it possesses an enzymatic activity called tautomerase activity, and it interacts with a specialized surface receptor called CD74.
MIF influences a wide range of biological processes: it promotes inflammation, helps tumors evade immune destruction, enhances resistance to chemotherapy, and drives tumor metastasis through stabilization of signaling pathways like beta-catenin. Its involvement in so many cancer-promoting processes makes it an attractive therapeutic target if a safe and effective inhibitor can be identified.
In colorectal cancer specifically, MIF had been linked to CXCR7-mediated chemotherapy resistance and general tumor promotion, but the precise molecular mechanism by which it drives CRC progression - and whether targeting it could be clinically useful - remained unclear. This study set out to resolve those questions systematically.
Integrating data from the TCGA, GTEx, CPTAC, and HPA databases, the researchers found that MIF mRNA and protein expression is significantly elevated in colorectal cancer tumor tissues compared to normal colorectal tissue. This overexpression was consistent across multiple independent databases and validated in 21 paired tumor and adjacent normal tissue samples collected directly from CRC patients.
Survival analysis revealed that CRC patients with high MIF expression had significantly shorter overall survival (OS) and disease-specific survival (DSS), particularly in Stage I and II patients where the cancer had not yet spread widely. This early-stage association is important: it suggests MIF's upregulation is not just a late-stage effect but an early, driving event in colorectal carcinogenesis.
Examining MIF expression across different TNM pathological stages (the standard system for staging cancer by tumor size, lymph node involvement, and metastasis), MIF was consistently elevated compared to normal tissue at all stages. The peak expression in early-stage samples supports the hypothesis that MIF-driven changes are initiating events in CRC rather than consequences of advanced disease.
To identify exactly which cells within the tumor are producing MIF, the researchers analyzed two single-cell RNA sequencing (scRNA-seq) datasets: GSE166555 and GSE144735. After quality control and batch correction, 82,865 individual cells were analyzed, enabling identification of seven distinct cell types within colorectal tumors.
Among all cell types, MIF expression was most prominent in epithelial cells. When epithelial cells from tumor tissue were further subdivided using computational tools to distinguish malignant from non-malignant epithelial cells, MIF was significantly higher in the malignant epithelial subpopulation. This precision is meaningful - it shows that cancer cells themselves are the primary MIF producers, not the surrounding immune or stromal cells.
The single-cell analysis also revealed that MIF-positive malignant cells display strong autocrine signaling - they secrete MIF and then respond to it themselves through surface receptors, creating a self-reinforcing loop. Analysis of ligand-receptor interactions identified MIF-CD74 as the dominant autocrine signaling pair in MIF-expressing malignant cells, establishing CD74 as the key downstream receptor through which MIF acts in CRC.
Normal cells generate most of their energy by burning glucose through oxidative phosphorylation in the mitochondria - an efficient process that produces large amounts of ATP. In contrast, cancer cells preferentially convert glucose to lactate through glycolysis even when oxygen is plentiful, a phenomenon called the Warburg effect, named after biochemist Otto Warburg who first observed it over a century ago.
Although glycolysis is far less efficient at generating ATP than oxidative phosphorylation, cancer cells exploit it because it simultaneously generates building blocks for cell growth (nucleotides, amino acids, lipids) and creates an acidic, lactate-rich microenvironment that suppresses immune cell function. This metabolic shift confers advantages in proliferation, therapy resistance, and immune evasion.
Key enzymes that execute this glycolytic program include HK2 (hexokinase 2, which initiates glucose breakdown), PKM2 (pyruvate kinase M2, which controls flux at a critical branch point), and LDHA (lactate dehydrogenase A, which completes the conversion of pyruvate to lactate). Overexpression of these enzymes is a hallmark of highly glycolytic cancers and is associated with poor prognosis.
To establish the mechanistic link between MIF and glycolysis, the researchers created two engineered cell models: MIF-knockout LOVO cells (where MIF was eliminated using CRISPR-based sgRNA-2) and MIF-overexpressing DLD1 cells. Western blot analysis showed that MIF knockout dramatically reduced expression of HK2, PKM2, and LDHA, while MIF overexpression upregulated all three.
Metabolic measurements confirmed the functional consequences. Seahorse metabolic flux analysis - a technology that measures real-time oxygen consumption and acid production from living cells - showed that MIF knockout increased oxygen consumption (indicating more mitochondrial respiration) while decreasing extracellular acidification (indicating less glycolysis). MIF overexpression produced the opposite pattern, with high lactate and pyruvate production.
The CD74 receptor's role was confirmed using Milatuzumab, a humanized anti-CD74 antibody that blocks the receptor. Blocking CD74 downregulated HK2, PKM2, and LDHA and reduced glucose uptake and lactate production. Critically, adding extra MIF protein could not rescue glycolysis when CD74 was blocked - proving that CD74 is the essential receptor through which MIF drives the Warburg effect in CRC cells.
With the MIF-CD74-glycolysis axis validated as a therapeutic target, the researchers used computer-aided drug design to identify small molecules capable of blocking MIF's activity. Using Schrödinger software, they performed multistage virtual screening against a compound library of over 1,000 molecules, using the known three-dimensional structure of the MIF protein as the target.
The screening focused on MIF's tautomerase active site - the enzymatic pocket through which MIF exerts part of its biological activity and where the classical inhibitor ISO-1 also binds. Initial screening yielded 3,271 binding conformations, which were progressively filtered down to the most promising candidates based on predicted binding energy and key interactions with specific amino acid residues.
Key binding site analysis identified ILE64 as the core interaction site, with 1,595 molecules showing interaction at this position. After multi-stage filtering and ranking, the compound F3277-0933 emerged as the top candidate. Its predicted binding mode to the MIF tautomerase active site was favorable, and it was selected for experimental validation in cell and animal models.
Experimental validation confirmed that F3277-0933 inhibits MIF enzymatic activity with an IC50 of 8.284 micromolar - a measure of potency where lower values indicate stronger inhibition. When compared directly to ISO-1, the established benchmark inhibitor used in prior research, F3277-0933 demonstrated superior potency in suppressing MIF-driven glycolytic reprogramming and cell proliferation.
In cell culture experiments, F3277-0933 treatment significantly reduced the expression of HK2, PKM2, and LDHA, decreased glucose uptake, and lowered lactate and pyruvate production in CRC cell lines - mirroring the effects seen with MIF knockout. This confirmed that the inhibitor was working through the same MIF-CD74-glycolysis pathway that was mechanistically characterized in the preceding experiments.
In xenograft mouse models - where human CRC cells are implanted under the skin of immunodeficient mice to grow as tumors - F3277-0933 treatment produced significantly smaller tumor volumes and weights compared to controls. Histological analysis showed reduced Ki-67 staining (a marker of cell proliferation) in treated tumors, confirming that the drug suppressed tumor growth in a living organism, not just in cell culture.
The MIF-CD74-glycolysis axis identified in this study represents a novel, mechanistically distinct therapeutic opportunity for colorectal cancer. Over 50% of metastatic CRC patients fail current standard treatments including chemotherapy, targeted therapy, and immunotherapy - making identification of new druggable targets critically important for patients with treatment-resistant disease.
The finding that MIF overexpression peaks in early-stage CRC and correlates with poor survival suggests this pathway is active from the earliest stages of tumor formation. Early-stage patients whose tumors show high MIF expression might be candidates for MIF-targeted therapy as an adjuvant treatment after surgical resection, potentially preventing recurrence before it occurs.
The availability of a small-molecule inhibitor like F3277-0933 that can be administered orally (unlike antibody therapies) and that targets a well-defined active site provides a foundation for further drug development. However, important steps remain: toxicity profiling, pharmacokinetic studies, optimization of the molecule's properties, and eventually clinical trials in human patients to confirm safety and efficacy before this approach can reach the clinic.
This study presents a complete mechanistic narrative: MIF is overexpressed in malignant epithelial cells of colorectal cancer, where it binds to CD74 receptors on the same cells through autocrine signaling. This binding activates downstream signaling through ERK1/2 and AKT, ultimately upregulating glycolytic enzymes HK2, PKM2, and LDHA and driving the Warburg effect to fuel tumor growth and progression.
The research integrates multiple levels of evidence: large-scale multi-database analysis, single-cell sequencing of nearly 83,000 cells, CRISPR-based gene editing for functional validation, Seahorse metabolic flux analysis for real-time metabolic profiling, patient-derived organoids, xenograft mouse models, and computational virtual drug screening. This breadth of evidence makes the mechanistic conclusions particularly robust.
The identification of F3277-0933 as a high-potency MIF inhibitor that surpasses ISO-1 in suppressing CRC progression moves this research beyond basic discovery toward a potentially translatable therapeutic strategy. Combined with MIF's role as an early prognostic biomarker, this work establishes a scientifically compelling case for the MIF-CD74 axis as both a therapeutic target and a biomarker in precision colorectal cancer medicine.